Fady Ibraham Malik net worth and biography

Fady Malik Biography and Net Worth

EVP of Cytokinetics

Fady has been with Cytokinetics since our inception in 1998, serving in a variety of positions focused on building our cardiovascular and skeletal muscle programs from their conception, playing a key role in the preclinical and clinical progress of these programs. He is currently our Executive Vice President of Research and Development.

Since 2000, Fady has held an appointment in the Cardiology Division of the University of California, San Francisco, where he is currently a Clinical Professor. He was also a practicing Interventional Cardiologist at the San Francisco Veterans Administration Medical Center for over 18 years.

Dr. Malik received a B.S. from the University of California, Berkeley and his Ph.D. and M.D. from the University of California, San Francisco.

Fady is a native San Franciscan who enjoys travel, outdoor sports such as running and skiing, and spending time with his wife and three kids.

What is Fady Ibraham Malik's net worth?: The estimated net worth of Fady Ibraham Malik is at least $5.67 million as of December 10th, 2024. Dr. Malik owns 116,071 shares of Cytokinetics stock worth more than $5,672,390 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Malik may own. Additionally, Dr. Malik receives a salary of $839,660.00 as EVP at Cytokinetics. Learn More about Fady Ibraham Malik's net worth.
How old is Fady Ibraham Malik?: Dr. Malik is currently 60 years old. There are 4 older executives and no younger executives at Cytokinetics. The oldest executive at Cytokinetics is Dr. James A. Spudich Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 82 years old. Learn More on Fady Ibraham Malik's age.
What is Fady Ibraham Malik's salary?: As the EVP of Cytokinetics, Incorporated, Dr. Malik earns $839,660.00 per year. The highest earning executive at Cytokinetics is Mr. Robert I. Blum, President and Chief Executive Officer, who commands a salary of $1,330,000.00 per year. Learn More on Fady Ibraham Malik's salary.
How do I contact Fady Ibraham Malik?: The corporate mailing address for Dr. Malik and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Fady Ibraham Malik's contact information.
Has Fady Ibraham Malik been buying or selling shares of Cytokinetics?: During the last ninety days, Fady Ibraham Malik has sold $2,261,580.16 in Cytokinetics stock. Most recently, Fady Ibraham Malik sold 7,300 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.64, for a transaction totalling $369,672.00. Following the completion of the sale, the executive vice president now directly owns 116,071 shares of the company's stock, valued at $5,877,835.44. Learn More on Fady Ibraham Malik's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 48 times. They sold a total of 454,133 shares worth more than $28,606,030.33. The most recent insider tranaction occured on December, 16th when Director Wendall Wierenga sold 742 shares worth more than $36,068.62. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 12/16/2024.

Fady Ibraham Malik Insider Trading History at Cytokinetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Sell	7,300	$50.64	$369,672.00	116,071
11/26/2024	Sell	7,300	$50.16	$366,168.00	111,878
11/12/2024	Sell	6,342	$58.48	$370,880.16	113,878
10/30/2024	Sell	7,300	$51.91	$378,943.00	114,920
10/15/2024	Sell	7,300	$54.19	$395,587.00	116,920
10/1/2024	Sell	7,300	$52.10	$380,330.00	118,920
9/3/2024	Sell	7,384	$57.01	$420,961.84	122,920
8/6/2024	Sell	7,300	$53.71	$392,083.00	121,704
7/23/2024	Sell	7,300	$57.02	$416,246.00	129,004
7/9/2024	Sell	7,300	$55.90	$408,070.00	131,004
6/25/2024	Sell	7,300	$53.72	$392,156.00	133,004
6/11/2024	Sell	7,788	$53.04	$413,075.52	135,004
5/7/2024	Sell	15,547	$65.11	$1,012,265.17	137,056
4/9/2024	Sell	32,605	$74.31	$2,422,877.55	138,567
3/5/2024	Sell	32,604	$67.56	$2,202,726.24	138,973
2/6/2024	Sell	32,605	$79.30	$2,585,576.50	142,973
1/4/2024	Sell	15,678	$86.98	$1,363,672.44	146,973
11/9/2023	Sell	2,500	$35.40	$88,500.00	150,664
10/12/2023	Sell	2,500	$35.89	$89,725.00	153,164
9/14/2023	Sell	2,500	$34.86	$87,150.00	155,664
7/13/2023	Sell	2,500	$35.37	$88,425.00	160,664
6/8/2023	Sell	2,500	$38.07	$95,175.00	163,164
5/11/2023	Sell	1,787	$39.50	$70,586.50	165,396
5/3/2023	Sell	7,000	$40.00	$280,000.00	167,183
4/13/2023	Sell	4,000	$34.21	$136,840.00	167,183
3/9/2023	Sell	4,000	$39.10	$156,400.00	171,183
2/9/2023	Sell	4,000	$43.73	$174,920.00	152,589
1/12/2023	Sell	4,000	$40.47	$161,880.00	156,589
11/10/2022	Sell	4,000	$38.04	$152,160.00	164,346
10/13/2022	Sell	21,513	$47.28	$1,017,134.64	168,346
9/8/2022	Sell	21,500	$51.88	$1,115,420.00	168,346
7/14/2022	Sell	21,500	$43.43	$933,745.00	168,346
5/12/2022	Sell	13,987	$37.54	$525,071.98	168,084
4/7/2022	Sell	23,148	$42.58	$985,641.84	168,084
3/10/2022	Sell	26,852	$37.82	$1,015,542.64
12/9/2021	Sell	29,166	$36.49	$1,064,267.34
10/14/2021	Sell	2,000	$37.73	$75,460.00
9/9/2021	Sell	2,000	$31.43	$62,860.00
8/12/2021	Sell	2,000	$32.60	$65,200.00
7/8/2021	Sell	2,000	$19.48	$38,960.00
6/10/2021	Sell	2,000	$21.48	$42,960.00
5/13/2021	Sell	2,000	$24.42	$48,840.00
4/8/2021	Sell	2,000	$23.39	$46,780.00
3/11/2021	Sell	2,000	$19.90	$39,800.00
2/11/2021	Sell	1,632	$23.34	$38,090.88
1/14/2021	Sell	12,500	$19.25	$240,625.00
12/10/2020	Sell	1,052	$20.13	$21,176.76
11/12/2020	Sell	1,231	$17.15	$21,111.65
10/8/2020	Sell	1,258	$17.45	$21,952.10
9/10/2020	Sell	995	$22.85	$22,735.75
8/13/2020	Sell	599	$21.85	$13,088.15
7/9/2020	Sell	1,587	$26.96	$42,785.52
12/5/2019	Sell	1,500	$9.80	$14,700.00	121,350
11/7/2019	Sell	1,500	$9.98	$14,970.00	122,850
10/3/2019	Sell	1,500	$11.22	$16,830.00	122,067
9/5/2019	Sell	1,500	$13.69	$20,535.00	123,567
8/8/2019	Sell	1,500	$13.52	$20,280.00	125,067
7/11/2019	Sell	1,500	$11.26	$16,890.00	126,567
6/6/2019	Sell	1,500	$10.31	$15,465.00	128,067
5/2/2019	Sell	1,500	$8.29	$12,435.00	129,567
4/4/2019	Sell	1,500	$8.31	$12,465.00	131,067
3/7/2019	Sell	1,500	$5.98	$8,970.00	132,567
2/7/2019	Sell	1,500	$7.28	$10,920.00	84,067
1/10/2019	Sell	1,500	$7.31	$10,965.00	85,567
12/6/2018	Sell	1,500	$7.38	$11,070.00	87,067
11/1/2018	Sell	1,500	$6.68	$10,020.00	88,567
10/4/2018	Sell	1,500	$9.14	$13,710.00	90,067
9/6/2018	Sell	1,500	$8.00	$12,000.00	91,567
8/2/2018	Sell	1,500	$6.85	$10,275.00	93,067
7/5/2018	Sell	1,500	$9.05	$13,575.00	94,567
6/7/2018	Sell	3,000	$8.95	$26,850.00	96,067
11/1/2017	Sell	7,321	$13.39	$98,028.19	47,540
12/29/2016	Sell	5,633	$12.36	$69,623.88	3,361
12/30/2014	Sell	21,630	$6.73	$145,569.90

Fady Ibraham Malik Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $48.87

$46.85

$50.32

50 Day Range

MA: $52.09

$46.36

$58.62

2 Week Range

Now: $48.87

$36.24

$110.25

Volume

3,805,196 shs

Average Volume

1,988,956 shs

Market Capitalization

$5.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.

Fady Malik Biography and Net Worth

What is Fady Ibraham Malik's net worth?

How old is Fady Ibraham Malik?

What is Fady Ibraham Malik's salary?

How do I contact Fady Ibraham Malik?

Has Fady Ibraham Malik been buying or selling shares of Cytokinetics?

Who are Cytokinetics' active insiders?

Are insiders buying or selling shares of Cytokinetics?